- Home
- ARGX vs DD Comparison
ARGX vs DD Comparison
Compare ARGX & DD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- DD
- Stock Information
- Founded
- ARGX 2008
- DD 2015
- Country
- ARGX Netherlands
- DD United States
- Employees
- ARGX N/A
- DD N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- DD Major Chemicals
- Sector
- ARGX Health Care
- DD Industrials
- Exchange
- ARGX Nasdaq
- DD Nasdaq
- Market Cap
- ARGX 33.0B
- DD 28.5B
- IPO Year
- ARGX 2017
- DD N/A
- Fundamental
- Price
- ARGX $545.11
- DD $72.97
- Analyst Decision
- ARGX Strong Buy
- DD Buy
- Analyst Count
- ARGX 17
- DD 13
- Target Price
- ARGX $730.07
- DD $85.15
- AVG Volume (30 Days)
- ARGX 389.0K
- DD 2.3M
- Earning Date
- ARGX 07-24-2025
- DD 07-30-2025
- Dividend Yield
- ARGX N/A
- DD 2.25%
- EPS Growth
- ARGX N/A
- DD N/A
- EPS
- ARGX 15.94
- DD N/A
- Revenue
- ARGX $2,643,062,000.00
- DD $12,521,000,000.00
- Revenue This Year
- ARGX $61.64
- DD $6.20
- Revenue Next Year
- ARGX $32.00
- DD $4.25
- P/E Ratio
- ARGX $31.61
- DD N/A
- Revenue Growth
- ARGX 82.13
- DD 4.51
- 52 Week Low
- ARGX $429.27
- DD $53.77
- 52 Week High
- ARGX $678.21
- DD $90.06
- Technical
- Relative Strength Index (RSI)
- ARGX 41.20
- DD 66.43
- Support Level
- ARGX $510.06
- DD $67.73
- Resistance Level
- ARGX $563.36
- DD $69.81
- Average True Range (ATR)
- ARGX 15.45
- DD 1.41
- MACD
- ARGX -0.61
- DD 0.47
- Stochastic Oscillator
- ARGX 44.37
- DD 99.19
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to spin off its electronics business by the end of 2025, which will be named Qnity.